Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker De
The COVID-19 pandemic has placed enormous stress on both healthcare systems and researchers, and people all across the sector are looking for digital solutions to help ease the pressure.
Artificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them to start potentially life-saving treatment more quickly.
AI and machine learning drug development firm BenevolentAI has highlighted further data supporting its hypothesis that Eli Lilly’s Olumiant (baricitinib) could be a potential treatment for
Eli Lilly has enrolled the first patient into a phase 3 trial that is seeking to repurpose arthritis drug Olumiant as a treatment for people with COVID-19.